| Field | Specification |
|---|---|
| Applications | |
| Sensitivity | |
| Detection range | |
| Detection method | |
| Assay time | |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Scientific Background
This ELISA kit applies to the in vitro quantitative determination of Cr concentrations in serum, plasma and other biological fluids.
Assay Principle
This ELISA kit uses the Competitive-ELISA principle. The micro ELISA plate provided in this kit has been pre-coated with Universal Cr. During the reaction, Universal Cr in the sample or standard competes with a fixed amount of Universal Cr on the solid phase supporter for sites on the Biotinylated Detection Ab specific to Universal Cr. Excess conjugate and unbound sample or standard are washed away, and Avidin-Horseradish Peroxidase (HRP) conjugate are added to each micro plate well and incubated. Then a TMB substrate solution is added to each well. The enzyme-substrate reaction is terminated by the addition of stop solution and the color turns from blue to yellow. The optical density (OD) is measured spectrophotometrically at a wavelength of 450 nm ± 2 nm. The concentration of Universal Cr in tested samples can be calculated by comparing the OD of the samples to the standard curve.
Performance Specifications
| Sensitivity | 0.75 μg/mL |
|---|---|
| Detection Range | 1.25-80 μg/mL |
| Total Assay Time | 2 h 30 min |
| Compatible Sample Types | Serum, plasma and other biological fluids |
| Species Reactivity | Universal (multi-species validated) |
| Detection Method | Competitive |
| Precision (CV) | Both intra-CV and inter-CV are < 10%. |
| Recovery Rate | 80%-120% |
| Storage | 2-8℃,12 months |
✓ Research-Grade Validation
Specificity
This kit recognizes Universal Cr in samples.No significant cross-reactivity or interference between Universal Cr and analogues was observed
Safety & Regulatory
Handle reagents in accordance with institutional biosafety guidelines. Refer to the Safety Data Sheet (SDS) for complete hazard and handling information. Contains components that may require special disposal procedures per local regulations.
This kit is validated for use with Serum, plasma and other biological fluids. For unlisted matrices (e.g., tissue lysate, urine), perform a spike-and-recovery experiment to confirm assay performance before generating reportable data. Sample dilution in the kit's provided diluent is recommended to minimize matrix interference.
The minimum detectable concentration (sensitivity) of this kit is 0.75 μg/mL. Values below this threshold should be reported as below the limit of detection (<LOD) and should not be extrapolated from the standard curve.
The total assay time from sample addition to absorbance reading is approximately 2 h 30 min, including all incubation, wash, and substrate steps. Hands-on time is typically 1–2 hours; most steps involve passive plate incubation. Plan the assay as a single uninterrupted session for best results.
Standard components of this Competitive ELISA Kit typically include: pre-coated microplate (96-well strip format), lyophilized or liquid recombinant Cr standard, detection antibody, streptavidin-HRP conjugate, TMB substrate, stop solution, wash buffer concentrate, and sample/standard diluent. Refer to the kit insert or datasheet for the exact component list and storage requirements.
This kit uses colorimetric (TMB/HRP) detection and requires a standard microplate absorbance reader capable of measuring at 450 nm. A reference wavelength of 570 nm or 630 nm is recommended to reduce background. No specialized fluorescence or luminescence reader is needed. Ensure the instrument is calibrated and the plate is clean and free of condensation before reading.
Tissue samples may contain endogenous or exogenous proteases during processing, leading to degradation of extracted proteins. Therefore, it's necessary to add protease inhibitors during processing to ensure the integrity of target proteins. If customers can keep samples cold and handle them quickly during processing, omitting the protease inhibitor may not have a significant effect. After preparation, samples should be tested promptly or immediately aliquoted and frozen at -20°C or -80°C.
What is the range of enzyme activity of your IL-2 freeze-dried powder
What is the principle of adding stop solution to stop color reaction in ELISA experiment?
Can’t Find What You’re Looking For? We can help you source the best match or customize an ELISA solution for your study. Options may include alternative target synonyms, different species reactivity, sample type/matrix compatibility (serum/plasma/lysate/supernatant), assay format (sandwich/competitive), sensitivity/range, detection chemistry (colorimetric/fluorescent/chemiluminescent), plate format (pre-coated/uncoated, strips vs full plate), and bulk or custom packaging. Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.
Nanoparticle-inhibited neutrophil elastase prevents neutrophil extracellular trap and alleviates rheumatoid arthritis in C57BL/6 mice (2023) Nano Today. 10.1016/j.nantod.2023.101880
A single-domain antibody targeting factor XII inhibits both thrombosis and inflammation (2024) Nature Communications. 10.1038/s41467-024-51745-4
Resident Macrophage-Orchestrated Immune and Fibroblast Interactions in Immune Checkpoint Inhibitor-Associated Nephrotoxicity (2025) Advanced Science. 10.1002/advs.202505445
Dynamics of chromatin accessibility governing Gd-IgA1 synthesis in B cells associated with IgA nephropathy (2025) EXPERIMENTAL AND MOLECULAR MEDICINE. 10.1038/s12276-025-01505-1
Neutrophil extracellular traps-inhibited nanoplatform achieves comprehensive treatment of rheumatoid arthritis at different stages (2026) JOURNAL OF CONTROLLED RELEASE. 10.1016/j.jconrel.2026.114712
Celastrol-Loaded Bovine Serum Albumin Nanoparticles Target Inflamed Neutrophils for Improved Rheumatoid Arthritis Therapy (2023) Acta Biomaterialia. 10.1016/j.actbio.2023.11.028
“Y-type” PEG modified liposomes could eliminate the accelerated blood clearance (ABC) phenomenon and improved tumor therapy (2023) Applied Materials Today. 10.1016/j.apmt.2023.101853
Multi-Responsive Upconversion Hybrid Nanobots Clad with Dopamine for Light-Driven Breast Cancer Therapy (2026) ACS Applied Materials & Interfaces. 10.1021/acsami.5c20372
Manganese Dioxide-Based pH-Responsive Multifunctional Nanoparticles Deliver Methotrexate for Targeted Rheumatoid Arthritis Treatment (2025) Biomaterials Research. 10.34133/bmr.0187
Conjugation of the Fn14 Ligand to a SMAC Mimetic Selectively Suppresses Experimental Squamous Cell Carcinoma in Mice (2022) JOURNAL OF INVESTIGATIVE DERMATOLOGY. 10.1016/j.jid.2022.08.039
Effects of total flavones of Abelmoschus manihot (L.) on the treatment of diabetic nephropathy via the activation of solute carriers in renal tubular epithelial cells (2023) BIOMEDICINE & PHARMACOTHERAPY. 10.1016/j.biopha.2023.115899
Empagliflozin reduces kidney fibrosis and improves kidney function by alternative macrophage activation in rats with 5/6-nephrectomy (2022) BIOMEDICINE & PHARMACOTHERAPY. 10.1016/j.biopha.2022.113947
Abelmoschus Manihot ameliorates the levels of circulating metabolites in diabetic nephropathy by modulating gut microbiota in non-obese diabetes mice (2022) Microbial Biotechnology. 10.1111/1751-7915.14200
The efficacy and safety of intra-articular dual-acting antibacterial agent (TNP-2092) for implant infection-associated MRSA (2023) JOURNAL OF INFECTIOUS DISEASES. 10.1093/infdis/jiad588
Prediction of cellular targets in diabetic kidney diseases with single-cell transcriptomic analysis of db/db mouse kidneys (2022) Journal of Cell Communication and Signaling. 10.1007/s12079-022-00685-z
Dapagliflozin attenuates ferroptosis in diabetic nephropathy through activation of the Nrf2/HO?1 signaling pathway (2026) INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE. 10.3892/ijmm.2026.5842
Identification of the main flavonoids of Abelmoschus manihot (L.) medik and their metabolites in the treatment of diabetic nephropathy (2024) Frontiers in Pharmacology. 10.3389/fphar.2023.1290868
Evaluation of the efficacy of Abelmoschus manihot (L.) on diabetic nephropathy by analyzing biomarkers in the glomeruli and proximal and distal convoluted tubules of the kidneys (2023) Frontiers in Pharmacology. 10.3389/fphar.2023.1215996
Interaction between Plasma Metabolomics and Intestinal Microbiome in db/db Mouse, an Animal Model for Study of Type 2 Diabetes and Diabetic Kidney Disease (2022) Metabolites. 10.3390/metabo12090775
Salvianolic acid C, a novel pyroptosis inhibitor, attenuates podocyte injury in diabetic kidney disease through regulating miRNA-21/A20 pathway (2026) JOURNAL OF ETHNOPHARMACOLOGY. 10.1016/j.jep.2026.121589
Effects of Zhuang medicine compound Xiancao Granules on diabetic kidney disease: A multi-omics analysis (2023) JOURNAL OF ETHNOPHARMACOLOGY. 10.1016/j.jep.2023.117517
Fabrication and Evaluation of Quercetin Nanoemulsion: A Delivery System with Improved Bioavailability and Therapeutic Efficacy in Diabetes Mellitus (2022) Pharmaceuticals. 10.3390/ph15010070
KAT2A-mediated H3K79 succinylation promotes ferroptosis in diabetic nephropathy by regulating SAT2 (2025) LIFE SCIENCES. 10.1016/j.lfs.2025.123746
Apela inhibits systemic and renal inflammatory reactions in mice with type I cardiorenal syndrome (2021) FASEB JOURNAL. 10.1096/fj.202101030R
Solanum lycopersicum derived exosome-like nanovesicles alleviate restenosis after vascular injury through the Keap1/Nrf2 pathway (2024) Food & Function. 10.1039/D4FO03993A
